Zymeworks Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
ZYME$31.46+2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Income (Loss and Comprehensive
Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)
(In thousands except share and per share data)
(unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue | ||||
| License and milestone revenue | $250,000 | $25,250 | $250,000 | $88,184 |
| Viatris collaboration agreement revenue | 1,546 | — | 1,546 | — |
| Royalty and other revenue | 4,914 | 2,364 | 11,912 | 15,266 |
| Total revenue | 256,460 | 27,614 | 263,458 | 103,450 |
| Operating expenses: | ||||
| Research and development | 36,126 | 35,578 | 98,018 | 105,765 |
| Selling, general and administrative | 42,736 | 14,146 | 77,140 | 46,082 |
| Total operating expenses | 78,862 | 49,724 | 175,158 | 151,847 |
| Income (loss) from operations | 177,598 | (22,110) | 88,300 | (48,397) |
| Other (expense) income: | ||||
| Interest income | 2,473 | 3,529 | 8,471 | 10,379 |
| Interest expense related to sale of future revenue | (6,685) | — | (15,346) | — |
| Other (expense) income, net | (138) | 315 | 179 | (257) |
| Total other (expense) income, net | (4,350) | 3,844 | (6,696) | 10,122 |
| Income (loss) before income taxes | 173,248 | (18,266) | 81,604 | (38,275) |
| Income tax (expense) recovery | 452 | (1,336) | 2,915 | (1,646) |
| Net income (loss) | 173,700 | (19,602) | 84,519 | (39,921) |
| Other comprehensive (loss) income: | ||||
| Unrealized income (loss) on available for sale securities, net of tax of $0 | 35 | 290 | (580) | 902 |
| Total other comprehensive income (loss) | 35 | 290 | (580) | 902 |
| Comprehensive income (loss) | $173,735 | $(19,312) | $83,939 | $(39,019) |
| Net income (loss) per common share: | ||||
| Basic | $2.43 | $(0.26) | $1.16 | $(0.53) |
| Diluted | $2.28 | $(0.26) | $1.08 | $(0.53) |
| Weighted-average common stock outstanding: | ||||
| Basic | 71,609,790 | 75,767,778 | 73,079,426 | 75,427,508 |
| Diluted | 76,252,275 | 75,775,214 | 78,173,571 | 75,434,487 |
The accompanying notes are an integral part of these financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.